1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma.
Saved in:
| Title: | 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. |
|---|---|
| Authors: | Butler, M.O.1 (AUTHOR), Weight, R.2 (AUTHOR), Haq, R.3 (AUTHOR), Javed, A.4 (AUTHOR), Chandana, S.5 (AUTHOR), Chmielowski, B.6 (AUTHOR), Dummer, R.7 (AUTHOR), Carlino, M.S.8 (AUTHOR), Mckean, M.9 (AUTHOR), Moser, J.10 (AUTHOR), Chandrasekaran, S.11 (AUTHOR), Khan, S.12 (AUTHOR), Kim, K.B.13 (AUTHOR), Lutzky, J.14 (AUTHOR), Shackleton, M.15 (AUTHOR), Atkinson, V.G.16 (AUTHOR), Beaupre, D.17 (AUTHOR), Cole, G.W.18 (AUTHOR), Patel, H.19 (AUTHOR), Orloff, M.20 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS747-S747. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.2142 |
